Main Facts
Science Corporation, a pioneering neurotechnology firm founded by former Neuralink president and co-founder Max Hodak, has reached a monumental milestone in the field of brain-computer interfaces (BCIs). Speaking on stage at TechCrunch Disrupt, Hodak announced that the company successfully implanted its flagship vision-restoring microchip, known as PRIMA, into its first patient suffering from Stargardt disease—an inherited, progressive, and historically incurable genetic eye condition that gradually destroys central vision.
The procedure, performed in May at the Sydney Eye Hospital in Australia, marks a significant step forward in translating advanced neural engineering into practical, life-changing medical treatments. The PRIMA system represents a paradigm shift in how science approaches degenerative blindness. Rather than attempting to repair damaged biological tissue, the technology bypasses dead photoreceptors entirely, acting as an artificial retina. Patients wear specialized glasses equipped with an integrated micro-camera that captures their visual surroundings. This visual data is then processed and beamed directly as infrared light pulses onto a tiny, 2-millimeter by 2-millimeter wireless chip surgically implanted beneath the retina.
While PRIMA has already achieved commercial approval in Europe for individuals suffering from geographic atrophy—an advanced, blinding form of age-related macular degeneration—this latest clinical application proves its adaptability. Stargardt disease affects approximately 150,000 people worldwide, progressively eroding the outer retina while often sparing the inner neural pathways that carry signals to the brain. By directly stimulating these surviving pathways, Science Corporation is opening doors to restoring functional sight in patients who previously had no medical recourse.
Chronology
To understand the weight of Science Corporation’s current clinical achievements, it is necessary to trace the trajectory of Max Hodak’s work in the neurotechnology landscape:
- 2021: Following his departure from Neuralink—where he served as president and co-founder—Max Hodak establishes Science Corporation with a vision to explore a broader array of neural engineering and medical device applications, stepping away from strictly invasive, computer-control-focused brain implants.
- December 2025: Science Corporation details its unique intracranial approach, confirming that its broader BCI sensor technology is designed to sit safely on top of the brain inside the skull, distinguishing it from implants that pierce deep into cortical tissue.
- April 2026: Science Corporation highlights the regulatory and developmental momentum surrounding the PRIMA chip, paving the way for expanded human trials targeting severe vision loss.
- May 2026: Surgeons at the Sydney Eye Hospital in Australia perform the first PRIMA implantation on a patient with Stargardt disease. During initial post-operative rehabilitation sessions, the patient rapidly transitions from recognizing isolated letters to reading whole words.
- July 2026: The PRIMA vision-restoring chip achieves official European regulatory approval for geographic atrophy patients, marking a critical commercial milestone for the company.
- October 2026: Max Hodak officially announces the successful Stargardt disease clinical trial results at TechCrunch Disrupt, simultaneously outlining the company’s ambitious roadmap for neurodegenerative diseases, stroke rehabilitation, and long-term health span extension.
Supporting Data and Technical Architecture
The technical execution of the PRIMA implant relies on precision engineering designed to interface seamlessly with the central nervous system. Because the retina is fundamentally an extension of the central nervous system, Hodak emphasizes that retinal prostheses, cochlear implants, and motor prostheses are all valid, interconnected classifications of brain-computer interfaces.
The Mechanics of Sight Restoration
The PRIMA chip operates on a remarkably elegant premise: to the human brain, vision is nothing more than electrical potential traveling down the optic nerve. By artificially replicating this electrical signaling, the brain interprets the data as native sight.
- Implant Dimensions: The wireless photovoltaic chip measures a mere 2mm by 2mm.
- Procedure Duration: The surgical intervention to place the microchip beneath the degenerated photoreceptors takes approximately one hour.
- Visual Field and Acuity: Due to the small size of the current chip, patients experience what Hodak describes as "looking through a straw." The restored vision is delivered as a high-contrast, sharp, black-and-white patch in the center of their visual field, allowing them to read a couple of letters at a time.
- Clinical Progression: During the patient’s inaugural rehabilitation session at Sydney Eye Hospital, they successfully identified a single letter. By the second session, they were capable of reading complete words.
- Next-Gen Engineering Goals: Science Corporation is actively developing a second-generation chip slated for human trials within the next year. Over the next five years, the company aims to engineer implants with significantly larger fields of view and smaller electrode configurations, ultimately matching native visual acuity and working around the natural curvature of the eye.
Beyond vision, Science Corporation’s intracranial BCI sensor technology is designed to rest comfortably on the surface of the brain beneath the skull, offering a less disruptive profile than traditional intracortical spikes like those utilized by Neuralink.
Official Responses and Strategic Vision
During his keynote address at TechCrunch Disrupt, Max Hodak elaborated on Science Corporation’s overarching philosophy. Rather than chasing the futuristic sci-fi trope of merging healthy humans with machines, Hodak’s strategy is rooted in medical pragmatism and a sustainable business model.
"When I was saying the brain’s a computer, vision is electrical potential… that’s all vision is to the brain," Hodak stated on stage. "And so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it."
By addressing blinding eye diseases first, Science Corporation secures a reliable pathway for commercial viability and regulatory approval while refining its core neuro-stimulation technology. However, vision restoration is only the tip of the iceberg.
Hodak revealed that the company is quietly preparing to launch clinical trials for a widely recognized neurodegenerative disease—an indication the company has not yet publicly named. Furthermore, Science Corporation is setting its sights on stroke recovery. By establishing deep-brain connections across separated, damaged cortical areas, Hodak suggests the technology could theoretically bridge dead tissue gaps, effectively adding new functional brain regions—a feat impossible with conventional medical electrodes.
Looking decades ahead, Hodak articulated an even grander mission: "The long-term mission of the company is to understand how the brain creates the mind and to learn to build engineered brains." While the company is not actively targeting healthy 40-year-olds, Hodak predicts that brain-computer interfaces will become commonplace medical interventions as humans reach their sixties and seventies. "We want to figure out how do we extend not just lifespan, but health span," he concluded.
Implications
The successful implantation of the PRIMA chip in a Stargardt disease patient and the broader ambitions of Science Corporation carry profound implications for medicine, technology, and society at large.
1. A Paradigm Shift in Ophthalmology and Neurology
For centuries, degenerative retinal diseases like Stargardt disease and age-related macular degeneration were viewed as irreversible tragedies. The success of photovoltaic retinal prostheses proves that neuro-electronic bridging can successfully restore sensory input. As electrode density increases and fields of view expand over the coming half-decade, millions of legally blind individuals could regain independent reading, navigation, and facial recognition capabilities.
2. Expanding the Definition and Acceptance of BCIs
For years, public perception of BCIs has been dominated by high-profile projects focused on computer cursor control or futuristic transhumanist concepts. By framing cochlear implants, retinal chips, and neural sensors under a unified BCI umbrella, Science Corporation is normalizing neurotechnology as standard medical hardware. This healthcare-first approach builds immediate public trust and secures regulatory pathways.
3. Transforming Stroke and Neurodegenerative Treatment
The prospect of bypassing dead neural tissue following a stroke—or creating functional bridges across damaged brain regions—could rewrite the playbook for neurological rehabilitation. Conditions that currently result in permanent paralysis, cognitive decline, or loss of motor function may soon find relief through surface-level, biocompatible sensor arrays that assist or regenerate lost neurological pathways.
4. Redefining Aging and Health Span
Hodak’s prediction that BCI adoption may become routine by age 60 or 70 points toward a future where neurotechnology is integrated into preventative geriatric care. Just as pacemakers became standard interventions for failing hearts, neural prosthetics and monitoring sensors may become standard tools to protect cognitive and sensory faculties as the global population ages.
Through meticulous clinical execution, deliberate commercial sequencing, and radical long-term ambition, Science Corporation is turning the theoretical promise of neurotechnology into tangible, sight-restoring reality—proving that the boundary between biology and electronics is no longer a barrier, but a bridge.
Lina Hope
Suro Senen
Sagoh
